Trends in treatment of non-small cell lung cancer in Finland 2014–2019

Leskelä, Riikka‐Leena; Peltonen, Emmi; Haavisto, Ira; Herse, Florian; Korhonen, Sonja; Nolvi, Katja; Käkelä, Sari; Autere, Anna-Maija; Tiainen, Satu; Silvoniemi, Maria; Junnila, Eeva-Liisa; Ahvonen, Jarkko; Knuuttila, Aija; Koivunen, Jussi

doi:10.1080/0284186x.2022.2042474

Cited by 3 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study, being the first one in Finland, described the real-world characteristics, overall survival, and healthcare resource utilization of Finnish locally advanced and unresectable or metastatic NCSLC patients by KRAS mutation status. Some studies have recently examined the real-world treatments and outcomes of NSCLC patients in Finland [21][22][23], but no analyses on patients with KRAS mutation and their survival have been published. In the current study, altogether 601 patients with locally advanced and unresectable or metastatic NSCLC were identified, out of which 383 were tested with NGS.…”

Section: Discussionmentioning

confidence: 99%

Real-World Evidence Study of Patients with KRAS-Mutated NSCLC in Finland

Anttalainen,

Pietarinen,

Tuominen

et al. 2024

Current Oncology

Self Cite

View full text Add to dashboard Cite

While KRAS is the most frequently mutated oncogene in non-small cell lung cancer (NSCLC), KRAS-mutant tumors have long been considered difficult to treat and thus, an unmet need still remains. Partly due to the lack of targeted treatments, comprehensive real-world description of NSCLC patients with KRAS mutation is still largely missing in Finland. In this study, all adult patients diagnosed with locally advanced and unresectable or metastatic NSCLC from 1 January 2018 to 31 August 2020 at the Hospital District of Helsinki and Uusimaa were first identified in this retrospective registry-based real-world study. The final cohort included only patients tested with next generation sequencing (NGS) and was stratified by the KRAS mutation status. A total of 383 patients with locally advanced and unresectable or metastatic NSCLC and with NGS testing performed were identified. Patients with KRAS mutation (KRAS G12C n = 35, other KRAS n = 74) were younger than patients without KRAS mutations, were all previous or current smokers, and had more often metastatic disease at diagnosis. Also, these patients had poorer survival, with higher age, Charlson comorbidity index (CCI) being 5 or above, and KRAS G12C being the most significant risk factors associated with poorer survival. This suggests that the patients with KRAS mutation have a more aggressive disease and/or tumors with KRAS mutation are more difficult to treat, at least without effective targeted therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

Real-World Evidence Study of Patients with KRAS-Mutated NSCLC in Finland

Anttalainen,

Pietarinen,

Tuominen

et al. 2024

Current Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…The trend in histological distribution of lung cancer has been similar in the other countries. [27][28][29] According to a national lung cancer report for Sweden in 2021, over 50% of patients were diagnosed with metastasis but the majority of patients with good performance status (WHO grades up to 2) were offered some form of treatment; half of all diagnoses were in the age group 70 to 79 years (https://cancercentrum.se/samverkan/cancerdiagnoser/lunga-ochlungsack/kvalitetsregister). In Norway in the period 1997-2011 about half of lung cancers were diagnosed with metastases and there was a time-dependent increase in resection rates from 16.3% in 1997-99 to 23.8% in 2009-11.…”

mentioning

confidence: 99%

“…31 Positron emission tomography (PET) was introduced in Sweden in 1990 and together with thorax-CT it has become a diagnostic tool for most lung cancer patients. [27][28][29] A further improvement in the diagnostic armamentarium was endobronchial ultrasound bronchoscopy (EBUS) which Sweden started using after the year 2000. 28 Surgery, often minimally invasive surgery, is the main therapeutic modality for early-stage lung cancer, supported by radio-or chemotherapy and more recently by targeted therapy or immunotherapy.…”

mentioning

confidence: 99%

“…28 Surgery, often minimally invasive surgery, is the main therapeutic modality for early-stage lung cancer, supported by radio-or chemotherapy and more recently by targeted therapy or immunotherapy. 29,32,33 Non-small cell lung cancer develops resistance toward chemotherapy and targeting radiation needs to be adjusted to movements because of breathing. Surgery, chemotherapy with platinum and other compounds, targeted therapy (eg, epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangement) and immunotherapy are currently the treatments of choice; immunotherapy is widely used as single agent, if the tumor is PDL1+ or tumor mutation burden is high.…”

mentioning

confidence: 99%

“…The previous studies on lung cancer survival ascribe the progress to multifactorial causes including earlier and more precise diagnostics, improved and more active treatment, and better organization of patient care. 23,[27][28][29] Also, the gradual shift in lung cancer histology from squamous cell carcinoma to a more tractable adenocarcinoma should contribute to a survival benefit. 28,33 The title of one of these studies "Lung cancer survival in Norway, 1997-2011: from nihilism to optimism" epitomized the combined contribution of many positive factors.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Survival in Lung Cancer in the Nordic Countries Through A Half Century

Tichánek¹,

Försti²,

Hemminki³

et al. 2023

CLEP

View full text Add to dashboard Cite

Lung cancer is often diagnosed at an advanced stage and survival has been poor, although long-term studies have been rare. We analyzed data on survival in lung cancer from Denmark, Finland, Norway, and Sweden over a 50-year period . Methods: Relative 1-and 5-year survival data were obtained from the NORDCAN database for 1971-2020. We used generalized additive models to estimate survival trends over time and uncertainty of these estimates. We additionally calculated conditional survival from the 1st to 5th year (5/1-year), estimated annual changes in survival rates, and determined significant breaking points. Results: In 2016-2020, 5-year survival rate for lung cancer was best for Norwegian men (26.6%) and women (33.2%). The sex difference was significant and it was found for each country. Survival improved modestly until the year 2000, after which time survival curves increased steeply and kept the linear shape to the end of follow-up, indicating consistent improvement in survival. Survival curves for 1-and 5/1-year survival were almost superimposable, indicating that deaths in the first year were approximately as many as in the subsequent 4 years, thus marking sustained long-term survival. Conclusion:We could document a positive development in lung cancer survival with steep upward trends after the year 2000. Intensions for curative treatment have been increasing and the outcomes have been improving with the help of novel imaging methods. Pathways for facile patient access to treatment have been instituted. Close to 90% of the patients are ever smokers. National antismoking acts and alerting people who smoke about early symptoms may be beneficial, as metastatic lung cancer remains difficult to cure.

show abstract